[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphatic-metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphatic-metastasis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,59,85,109,133,155,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":5},"100604190","implementation-of-indocyanine-green-to-identify-sentinel-lymph-nodes-during-surgery-for-breast-cancer-100604190",false,"NCT07146295","Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer","Implementation of Fluorescence Imaging Using Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer","INFINITE","Inclusion Criteria:\n\n* Patients ≥ 18 years old.\n* DCIS or invasive breast cancer, confirmed by biopsy\n* Clinically node-negative, confirmed by preoperative axillary ultrasound\n* Indication for breast cancer surgery with SLN procedure via axillar incision\n\nExclusion Criteria:\n\n* Combined MARI procedure\n* Known allergy for Indocyanine Green (ICG), intravenous contrast or iodine\n* History of axillary lymph node dissection\n* Hyperthyroidism or thyroid cancer\n* Pregnancy or breast-feeding\n* No written informed consent according to ICH\u002FGCP and national regulations.","ALL","18 Years",{"count":20,"type":21},1760,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn how to successfully introduce a new method for finding the sentinel lymph node during breast cancer surgery into routine hospital care. The method uses a dye called indocyanine green (ICG) and a special camera to see the lymph node. The sentinel lymph node is the first lymph node that cancer is likely to spread to.\n\nIn the Netherlands, about 1 in 7 women develops breast cancer. Finding out whether cancer has spread to the lymph nodes is important for planning treatment and predicting outcomes. The current standard method for sentinel lymph node biopsy (SLNB) uses a radioactive tracer called radioisotope technetium-labeled (99mTc)-nanocolloid. While accurate, this method has several drawbacks: it exposes patients to radioactivity, requires an extra hospital visit or travel to another hospital due to limited nuclear medicine facilities, and is not sustainable. Surgeries using 99mTc can only take place on certain days due to logistical issues, and the signal from 99mTc can be disturbed by the tumor marker placed in the breast.\n\nICG works as well as 99mTc for SLNB and offers several advantages: it is given during surgery (no extra visit needed), produces no radiation, and reduces costs. However, it is still not widely used in the Netherlands because hospitals may not be familiar with it or unsure how to make the switch.\n\nThis study will introduce ICG step-by-step in several Dutch hospitals and evaluate how to make the change as smooth and effective as possible. It will take place in three stages: I) SLNB with 99mTc only (current practice); II) SLNB with both 99mTc and ICG (transition phase); III) SLNB with ICG only (full implementation).\n\nAll study procedures take place during planned surgery, with no extra hospital visits. After surgery, participants will receive a short questionnaire (10-15 minutes) to share their experiences with the procedure. Their feedback, combined with input from healthcare providers, will help researchers develop a uniform medical protocol, an implementation guide, and educational materials for surgeons and surgical trainees.\n\nThe aim is to make ICG widely available across the Netherlands, ensuring that care is less burdensome, more sustainable, and more cost-effective, while keeping treatment accessible in local hospitals.",[27,28,29,30,31,32,33,34,35],"Breast Cancer","Sentinel Lymph Node Biopsy (SLNB)","Sentinel Lymph Node Detection","Sentinel Lymph Node","Lymphatic Metastasis","Fluorescence Imaging","Indocyanine Green (ICG)","Radioisotopes","Lymph Node Mapping",[37,38,39,40,41,42,43,44,45,46],"Breast cancer","Sentinel lymph node biopsy","Lymphatic metastasis","Indocyanine green","Techetium nanocolloïd","Fluorescence imaging","Surgical oncology","Lymph node mapping","Implementation","Radioisotope","RECRUITING","2026-06-22",{"date":50,"type":51},"2026-06-25","ACTUAL",{"date":53,"type":51},"2025-04-18",{"date":55,"type":21},"2026-08",{"name":57,"class":58},"Isabelle Henskens","OTHER",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":66,"minAge":18,"maxAge":67,"enrollmentInfo":68,"targetDuration":70,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100637051","ultrasound-guided-core-needle-biopsy-to-assess-sensitivity-and-specificity-of-axillary-lymph-node-metastasis-in-breast-cancer-100637051","NCT07573657","Ultrasound-Guided Core Needle Biopsy to Assess Sensitivity and Specificity of Axillary Lymph Node Metastasis in Breast Cancer","Sensitivity and Specificity of Ultrasound-Guided Core Needle Biopsy in Evaluating Axillary Lymph Node Metastasis in Breast Cancer","Inclusion Criteria:\n\n1. Age ≥18 years and \\\u003C70 years;\n2. Histologically confirmed primary breast cancer;\n3. Underwent ultrasound examination to assess axillary lymph node metastasis status.\n\nExclusion Criteria:\n\n1. Presence of other malignancies (e.g., lymphoma, lung cancer, thyroid cancer, etc., with axillary metastasis);\n2. Pregnant or lactating women;\n3. Previous receipt of neoadjuvant radiotherapy or chemotherapy;\n4. Lymph node metastasis status not confirmed by pathology, or time interval between ultrasound examination and pathological confirmation exceeding 6 weeks.","FEMALE","70 Years",{"count":69,"type":21},200,"10 Days","OBSERVATIONAL","This study plans to find the most suitable lymph node cortex thickness and abnormal lymph node features to define suspicious lymph nodes. Then, ultrasound-guided core needle biopsy of axillary lymph nodes will be done, aiming to provide some guidance for the biopsy.",[31,74],"Breast Neoplasms","NOT_YET_RECRUITING","2026-05-01",{"date":78,"type":51},"2026-05-07",{"date":80,"type":21},"2026-10-01",{"date":82,"type":21},"2028-10-01",{"name":84,"class":58},"The First Hospital of Jilin University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100634323","iparomlimab-and-tuvonralimab-plus-chemotherapy-before-surgery-for-stage-iii-lung-cancer-100634323","NCT07538193","Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer","A Study of Iparomlimab and Tuvonralimab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Stage III-N2b Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Voluntarily join the study and sign the Informed Consent Form (ICF).\n2. ≥18 years old, male or female.\n3. Histologically or cytologically confirmed T\\\u003Csub\\>any\\\u003C\u002Fsub\\>N2b stage NSCLC (American Joint Committee on Cancer \\[AJCC\\] 9th edition). Lymph node status must be confirmed by endobronchial ultrasound (EBUS\u002FEUS) or mediastinoscopy for mediastinal lymph nodes. For left-sided stations 5\u002F6 lymph nodes, parasternal mediastinoscopy is recommended to confirm lymph node status; if mediastinoscopy is not performed, station 5\u002F6 lymph node status is diagnosed based on imaging diagnostic criteria.\n4. Based on MDT assessment (which must include a thoracic surgeon specialized in oncology), the primary NSCLC is deemed to be completely resectable (R0).\n5. At least one measurable lesion as assessed by the investigator per RECIST v1.1.\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n7. Adequate organ function meeting the following requirements (no use of any blood components, cell growth factors, etc., within 14 days before the first dose):\n\n   1. Absolute neutrophil count ≥1.5×10⁹\u002FL;\n   2. Platelet count ≥100×10⁹\u002FL;\n   3. Hemoglobin ≥90 g\u002FL;\n   4. Serum creatinine ≤1.5×upper limit of normal (ULN) or creatinine clearance (CLcr) ≥40 mL\u002Fmin calculated by the Cockcroft-Gault formula;\n   5. Total bilirubin ≤1.5×ULN (patients with Gilbert's syndrome may have ≤3×ULN);\n   6. AST and ALT ≤3×ULN;\n   7. International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN, unless the subject is receiving anticoagulant therapy;\n   8. Left ventricular ejection fraction (LVEF) ≥50%.\n8. For female patients of non-surgical sterilized or childbearing potential, must agree to use a medically accepted contraceptive method (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment period and for 3 months after the study treatment period ends; female patients of childbearing potential who are not surgically sterilized must have a negative serum or urine HCG test within 72 hours before the first dose; and must be non-lactating; for male patients with partners of childbearing potential, must agree to use effective contraception during the trial and for 3 months after the last dose of Iparomlimab\u002FTuvonralimab.\n\nExclusion Criteria:\n\n1. Known presence of EGFR or ALK positive mutations.\n2. History of or concurrent other malignancy within the past 5 years (excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery).\n3. Prior receipt of any anti-tumor therapy for the current lung cancer (e.g., radiotherapy, chemotherapy, targeted therapy, ablation, or other systemic or local anti-tumor therapies).\n4. Current use of immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose \\>10 mg\u002Fday prednisone or equivalent) and continued use within 2 weeks before enrollment (Note: Inhaled or topical corticosteroids and adrenal replacement steroids are permitted in the absence of active autoimmune disease).\n5. Any active autoimmune disease or history of autoimmune disease, including but not limited to: autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism.\n\n   1. Subjects with hypothyroidism controlled by hormone replacement therapy alone are eligible;\n   2. Subjects with skin diseases not requiring systemic treatment such as vitiligo, psoriasis, alopecia, type 1 diabetes, or childhood asthma that has completely resolved and requires no intervention in adulthood are eligible;\n   3. Patients with asthma requiring medical intervention with steroids are not eligible.\n6. History of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation).\n7. Congenital or acquired immunodeficiency (e.g., HIV-infected individuals).\n8. Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] test at screening with concurrent HBV-DNA test value above the upper limit of normal of the research center's laboratory; subjects with HBV-DNA \\\u003C500 IU\u002FmL measured within 28 days before study drug administration and who have received standard local antiviral therapy for at least 4 weeks and are willing to continue antiviral therapy during the study may be enrolled). Subjects with active hepatitis C (defined as positive hepatitis C virus antibody \\[HCsAb\\] test at screening and positive HCV-RNA).\n9. History of severe allergic reactions to other monoclonal antibodies.\n10. Vaccination with live vaccine within 30 days before the first dose of study treatment (continuing until 90 days after the last dose of study treatment). Note: Live vaccines include but are not limited to measles, mumps, rubella, varicella\u002Fzoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccines. Inactivated seasonal influenza vaccines, inactivated COVID-19 vaccines, etc., are permitted.\n11. Clinically significant cardiovascular or cerebrovascular diseases, including but not limited to:\n\n    1. Myocardial infarction or unstable angina pectoris within 6 months before the first dose;\n    2. Stroke or transient ischemic attack within 6 months before the first dose;\n    3. Hypertension not controlled with optimal antihypertensive therapy (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n    4. Clinically significant arrhythmia that has been stable for ≥14 days before the first dose may be enrolled;\n    5. Congestive heart failure (New York Heart Association \\[NYHA\\] functional class III-IV);\n    6. Myocarditis.\n12. Systemic infection or other severe infection requiring intravenous antibiotics for \\>7 days within 2 weeks before the first study treatment, or unexplained fever \\>38.5°C during screening or before enrollment (fever due to tumor causes as judged by the investigator is excluded).\n13. Any other condition that, in the investigator's judgment, might affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concomitant treatment, severe laboratory abnormalities, or family or social factors, which could affect patient safety.",{"count":93,"type":21},28,[24],"Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation. Iparomlimab and tuvonralimab (QL1706) is a novel bifunctional antibody combination targeting PD-1 and CTLA-4, designed to enhance anti-tumor immunity.\n\nObjective: This phase II, single-arm, multicenter study aims to evaluate the efficacy and safety of neoadjuvant iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy in patients with resectable stage III-N2b NSCLC.\n\nStudy Design and Methods: A total of 28 patients will be enrolled across approximately 4 centers in China. Eligible patients (aged ≥18 years, ECOG PS 0-1) with histologically or cytologically confirmed, resectable stage III-N2b NSCLC (AJCC 9th edition) will receive three cycles of neoadjuvant therapy every three weeks. Patients with non-squamous carcinoma will receive iparomlimab and tuvonralimab (5 mg\u002Fkg) plus pemetrexed (500 mg\u002Fm²) and carboplatin (AUC 5). Patients with squamous carcinoma will receive iparomlimab and tuvonralimab (5 mg\u002Fkg) plus nab-paclitaxel (260 mg\u002Fm²) and carboplatin (AUC 5). Surgical resection will be performed within 6 weeks following completion of neoadjuvant therapy. Subsequent adjuvant treatment is at the discretion of the investigator.\n\nKey Eligibility Criteria: Key inclusion criteria include pathologically confirmed T\\\u003Csub\\>any\\\u003C\u002Fsub\\>N2b disease with mediastinal nodal status confirmed by EBUS\u002FEUS or mediastinoscopy, and the determination by multidisciplinary team (MDT) assessment that the tumor is completely resectable (R0). Key exclusion criteria include known EGFR or ALK positive mutations, prior anti-cancer therapy for current lung cancer, active autoimmune disease, or uncontrolled hepatitis B or C.\n\nStudy Endpoints: The primary endpoint is the pathological complete response (pCR) rate. Secondary endpoints include major pathological response (MPR) rate, objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), impact on surgical outcomes, and safety. Exploratory endpoints involve biomarker analysis including ctDNA.\n\nSample Size Rationale: Assuming a null hypothesis pCR rate (P0) of 8.8% (based on historical data) and an expected pCR rate (P1) of 28%, with a two-sided α of 5% and 80% power, 24 patients are required. Factoring in a 15% inoperable rate, the total sample size is 28 patients.\n\nStatistical Analysis: The primary endpoint, pCR rate, and other binary endpoints will be summarized with frequencies, percentages, and their 95% confidence intervals calculated using the Clopper-Pearson method. Time-to-event endpoints (EFS, OS) will be analyzed using the Kaplan-Meier method. Safety data will be summarized descriptively.\n\nClinical Trial Information: This study is sponsored by The Second Affiliated Hospital of Air Force Medical University, PLA. The Principal Investigator is Dr. Yan Xiaolong.",[97,98,31],"Carcinoma, Non-Small-Cell Lung (NSCLC)","Neoplasm Staging","2026-04-15",{"date":101,"type":51},"2026-04-20",{"date":103,"type":21},"2026-05",{"date":105,"type":21},"2029-12",{"name":107,"class":58},"Tang-Du Hospital",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":66,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100620812","finding-sentinel-lymph-nodes-during-mastectomy-using-indocyanine-green-inigma-study-100620812","NCT07362485","Finding Sentinel Lymph Nodes During Mastectomy Using Indocyanine Green (INIGMA Study)","Indocyanine Green Guided Identification of Sentinel Lymph Nodes Via Mastectomy Incision in Breast Cancer Patients (INIGMA Study)","INIGMA","Inclusion Criteria:\n\n* Clinically node-negative, DCIS, invasive T1- T3 breast cancer confirmed by biopsy.\n* Preoperative axillary ultrasound to confirm clinical node-negative status.\n* Indication (or preference) for mastectomy and simultaneous SLN procedure.\n* Written informed consent according to ICH\u002FGCP and national regulations.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old\n* Breast conserving surgery\n* Direct reconstruction (with autologous tissue or implant)\n* Known allergy for indocyanine green (ICG) or radioisotope technetium (99mTc), intravenous contrast or iodine\n* Other concurrent solid tumour\n* Hyperthyroidism or thyroid cancer\n* Pregnancy or breast feeding\n* Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol",{"count":118,"type":21},90,[24],"This pilot study evaluates the diagnostic value of indocyanine green (ICG) fluorescence for sentinel lymph node biopsy (SLNB) performed through the mastectomy incision in breast cancer patients.\n\nWomen with clinically node-negative, invasive T1-T3 breast cancer undergoing mastectomy with SLNB at St. Antonius or Isala Hospital will be included. All patients receive standard 99mTc injection preoperatively, followed by 5 mg (2mL) ICG injection after anesthesia. The axilla will be explored for fluorescent lymph nodes via the mastectomy incision, avoiding a separate axillary incision.\n\nPrimary outcome: ICG detection rate for SLN identification via the mastectomy incision.\n\nSecondary outcomes: Comparison with 99mTc detection, number of nodes identified, concordance between methods, pathology differences, detection time, and complications.\n\nICG is safe, non-ionizing, and causes no extra discomfort or visits. Risks and burden are minimal.",[27,28,29,30,31,32,33,34,35,122],"Mastectomy",[37,38,40,122,42,44,43,41,46],"2026-01-15",{"date":126,"type":51},"2026-01-23",{"date":128,"type":51},"2022-08-22",{"date":130,"type":21},"2026-06",{"name":57,"class":58},2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":108},"100564008","comparative-study-of-transaxillary-robotic-thyroidectomy-with-mrnd-versus-conventional-open-surgery-in-n1b-ptc-100564008","NCT06623578","Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC","Comparative Study of Transaxillary Robotic Thyroidectomy With Modified Radical Neck Dissection Versus Conventional Open Surgery in Patients With Papillary Thyroid Carcinoma and Lateral Neck Node Metastases: a Prospective Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-70 years old, male or female;\n* papillary thyroid carcinoma with ipsilateral lateral cervical lymph node metastasis confirmed by FNAB;\n* thyroid tumor of less than 3.0 cm in the largest diameter;\n* lack of extrathyroidal extensions as estimated by preoperative ultrasonography and CT.\n\nExclusion Criteria:\n\n* level I or contralateral neck node metastases.\n* enlarged lymph node of larger than 2.0 cm in the short diameter.\n* suspected perinodal infiltration of metastatic lymph nodes.\n* cervical or\u002Fand thoracic deformity.\n* life-threatening diseases of liver, kidney, heart and other organs, or abnormal coagulation function.\n* clinical evidence of distant metastases such as in the lung, bone, and so on.\n* history of previous neck surgery and\u002For radiation therapy.\n* intolerable to general anesthesia\n* refuse either surgical procedure\n* unwilling to cooperate with long-term follow-up evaluation.",{"count":141,"type":21},876,[24],"Thyroid cancer is one of the most common malignant tumors in women, ranking seventh in the United States and fourth in China. Papillary thyroid carcinoma is the most common pathological type (about 85% to 90% of thyroid cancers), and lateral cervical lymph node metastasis can reach 0.6-37.5% at diagnosis. For papillary thyroid cancer with lateral cervical lymph node metastasis, the 2015 ATA Guidelines in the United States recommend surgical resection and neck lymph node dissection as the primary treatment. Traditional cervical lymph node dissection often leaves obvious scars in the neck, which seriously affects the postoperative quality of life of patients. The previous studies have shown that endoscopy-assisted surgery with external cervical approach can achieve oncologic effects similar to traditional open surgery in the treatment of N1b papillary thyroid cancer, and can obtain better aesthetic results. However, endoscopic surgery still has some shortcomings, such as poor exposure of some surgical areas and difficult operation. Since November 2016, the investigators tried to apply modified transaxillary robotic-assisted surgery technology to the treatment of thyroid papillary carcinoma in China. The preliminary study included 30 patients, and the results showed that robot-assisted surgery via combined transaxillary-retroaural approach in the treatment of N1b papillary thyroid carcinoma achieved a good oncologic effect (5-year overall survival rate was 100.0%). As the surgical techniques improved, now the investigators can complete robotic-assisted lateral neck lymph node dissection via single-incision transaxillary approach. However, there is still a lack of high-quality evidence on the long-term oncologic outcome and quality of life of this procedure. In this study, a prospective, multi-center, randomized controlled study was conducted to compare the safety, long-term oncologic outcomes and postoperative quality of life of the robot-assisted surgery via single-incision transaxillary approach and open surgery in the treatment of N1b papillary thyroid cancer, which may provide an alternative for the patients with N1b papillary thyroid cancer.",[145,31],"Papillary Thyroid Carcinoma","2025-11-25",{"date":148,"type":51},"2025-12-03",{"date":150,"type":51},"2024-09-23",{"date":152,"type":21},"2033-12-31",{"name":154,"class":58},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":108},"100555891","development-and-prospective-validation-of-a-digital-pathology-based-artificial-intelligence-diagnostic-model-for-pan-cancer-lymphatic-metastasis-100555891","NCT06517979","Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis","Inclusion Criteria:\n\n* Patients with cancer, undergoing radical tumor resection and lymph node dissection.\n* Patients with complete clinical and pathological information.\n\nExclusion Criteria:\n\n* The patient refused to participate in this diagnostic test.",{"count":162,"type":21},10000,"The goal of this diagnostic test is to develop an artificial intelligence (AI)-based pan-cancer universal diagnostic model for detecting pathological lymph node metastasis (LNM), and prospectively evaluate its apllication value in the real-world clinical practice.\n\nInvestigators will compare the diagnostic performance (sensitivity, specificity, etc.) of the AI model and routine pathological report issued by pathologists, to see if the AI model can improve the clinical workflow of pathological evaluation of cancer LNM in in the real world.",[165,31],"Cancer",[167,168,169,170],"Artificial Intelligence","Lymph Node Metastasis","Digital Pathology","Whole Slide Image","2025-11-23",{"date":173,"type":51},"2025-11-28",{"date":175,"type":51},"2024-07-26",{"date":177,"type":21},"2027-06-30",{"name":154,"class":58},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":108},"100596248","ret-us-study---ultrasound-based-prediction-of-ret-alterations-and-lateral-neck-metastasis-in-thyroid-cancer-100596248","NCT07042984","RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer","RET-US Cohort: Prospective Evaluation of an AI-Ultrasound Model for Detecting RET Gene Alterations and Predicting Lateral Cervical Lymph-Node Metastasis in Papillary Thyroid Carcinoma","RET-US","Inclusion Criteria:\n\n* Age 18-75 years, able to provide written informed consent.\n* Pre-operative ultrasound findings highly suggestive of papillary thyroid carcinoma.\n* Planned thyroidectomy (any extent) at a participating institution.\n* Willing to undergo rapid 11-gene next-generation sequencing (NGS) panel and allow use of ultrasound DICOM images for AI analysis.\n\nExclusion Criteria:\n\n* Prior thyroid or major neck surgery.\n* Known medullary thyroid carcinoma, anaplastic carcinoma, or metastatic disease outside the neck.\n* Multiple endocrine neoplasia (MEN) syndromes or clinical suspicion of multi-gland disease.\n* Pregnant or breastfeeding.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or other condition that precludes surgery or gene testing.","75 Years",{"count":189,"type":21},800,"Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or \"AI\" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.\n\nWhat will happen in this study?\n\nAbout 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:\n\n* have a standard pre-operative ultrasound exam (no extra scanning time),\n* give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and\n* allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.\n\nMain goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.\n\nBenefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.",[145,192,193,31],"Thyroid Neoplasms","RET Proto-Oncogene Mutation",[195,167,196,197,198,199,200],"Ultrasound Radiomics","RET Fusion","BRAF V600E","Lateral Neck Metastasis","Deep Learning Model","11-Gene Panel","2025-06-21",{"date":203,"type":51},"2025-06-29",{"date":205,"type":21},"2025-07-01",{"date":207,"type":21},"2029-12-31",{"name":209,"class":58},"Fujian Medical University"]